Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:PZRX

PhaseRx (PZRX) Stock Price, News & Analysis

About PhaseRx Stock (NASDAQ:PZRX)

Key Stats

Today's Range
$0.28
$0.34
50-Day Range
$0.28
$0.28
52-Week Range
$0.22
$1.95
Volume
1.05 million shs
Average Volume
1.24 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

PhaseRx, Inc. operates as a biopharmaceutical company that develops a portfolio of mRNA products to correct inherited, life-threatening liver diseases in children. Its product portfolio targets the three urea cycle disorders ornithine transcarbamylase deficiency; argininosuccinate lyase deficiency; and argininosuccinate synthetase deficiency. The company was founded by Robert W. Overell, Patrick S. Stayton, Allan S. Hoffman, Oliver W. Press, and Paul H. Johnson on March 9, 2006 and is headquartered in Seattle, WA.

Receive PZRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PhaseRx and its competitors with MarketBeat's FREE daily newsletter.

PZRX Stock News Headlines

HUNTF Hunter Maritime Acquisition Corp.
PARD Poniard Pharmaceuticals, Inc.
Crypto’s hidden gem + greatest crypto bull run in history = $$$?
You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.
Powszechny Zaklad Ubezpieczen SA PZU
Nimbus Group AB (BOAT)
PhaseRx (PZRXQ) Earnings Dates & Reports
Tongwei Co Ltd (600438)
DeNA Co Ltd (2432)
See More Headlines

PZRX Stock Analysis - Frequently Asked Questions

PhaseRx, Inc. (NASDAQ:PZRX) announced its quarterly earnings results on Thursday, November, 9th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.14.

PhaseRx (PZRX) raised $18 million in an initial public offering (IPO) on Wednesday, May 18th 2016. The company issued 3,700,000 shares at $5.00 per share. Laidlaw & Company (UK) Ltd. and Roth Capital Partners acted as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that PhaseRx investors own include Avid Bioservices (CDMO), Immutep (IMMP), Arbutus Biopharma (ABUS), Allena Pharmaceuticals (ALNA), Biocept (BIOC), Eleven Biotherapeutics (EBIO) and Net Element (NETE).

Company Calendar

Last Earnings
11/09/2017
Today
12/22/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:PZRX
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
10 Best Stocks to Own in 2025 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:PZRX) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners